Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Pignon

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Seminars in Oncology|April 30, 2003
Transplantation in Waldenstrom's macroglobulinemia--the French experienceO Tournilhac, V Leblond, R Tabrizi, et al.
Blood|August 15, 1996
Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter studyE Solary, B Witz, D Caillot, et al.
Blood|November 5, 1997
Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM)J L Harousseau, J Y Cahn, B Pignon, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|September 19, 2022
3-year incidence and predictors of metabolic syndrome in schizophrenia in the national FACE-SZ cohortO Godin, B Pignon, A Szoke, et al.
Blood|May 16, 1998
A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM)F Witz, A Sadoun, M C Perrin, et al.
British Journal of Haematology|August 1, 1996
Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam GroupB Pignon, F Witz, B Desablens, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|March 17, 2020
Confirmations, advances and recommendations for the daily care of schizophrenia based on the French national FACE-SZ cohortG Fond, O Godin, F Schürhoff, et al.
European Archives of Psychiatry and Clinical Neuroscience|March 25, 2022
Early-life factors associated with increased risk of disability pension in the national real-world schizophrenia FACE-SZ cohort studyG Fond, J Dubreucq, P L Sunhary de Verville, et al.
Advances in Experimental Medicine and Biology|September 29, 1999
Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMSE Wattel, E Solary, B Hecquet, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|May 2, 2021
Redefining peripheral inflammation signature in schizophrenia based on the real-world FACE-SZ cohortG Fond, P L Sunhary de Verville, R Richieri, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Seminars in Oncology|April 30, 2003
Transplantation in Waldenstrom's macroglobulinemia--the French experienceO Tournilhac, V Leblond, R Tabrizi, et al.
Blood|August 15, 1996
Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter studyE Solary, B Witz, D Caillot, et al.
Blood|November 5, 1997
Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM)J L Harousseau, J Y Cahn, B Pignon, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|September 19, 2022
3-year incidence and predictors of metabolic syndrome in schizophrenia in the national FACE-SZ cohortO Godin, B Pignon, A Szoke, et al.
Blood|May 16, 1998
A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM)F Witz, A Sadoun, M C Perrin, et al.
British Journal of Haematology|August 1, 1996
Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam GroupB Pignon, F Witz, B Desablens, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|March 17, 2020
Confirmations, advances and recommendations for the daily care of schizophrenia based on the French national FACE-SZ cohortG Fond, O Godin, F Schürhoff, et al.
European Archives of Psychiatry and Clinical Neuroscience|March 25, 2022
Early-life factors associated with increased risk of disability pension in the national real-world schizophrenia FACE-SZ cohort studyG Fond, J Dubreucq, P L Sunhary de Verville, et al.
Advances in Experimental Medicine and Biology|September 29, 1999
Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMSE Wattel, E Solary, B Hecquet, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|May 2, 2021
Redefining peripheral inflammation signature in schizophrenia based on the real-world FACE-SZ cohortG Fond, P L Sunhary de Verville, R Richieri, et al.
Pageof 6